Program
EVO756
A development code. Also written as “EVO756, Dose 1”, “EVO756, Dose 2” and “Oral EVO756 300 mg QD”.
Its studies are mostly in Migraine Disorders · Dermatitis, Atopic · Chronic Urticaria, led by Evommune.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Evommune | 41 open or running | phase 2since Sep 17, 2024 | Sep 17, 2024 | Oct 2027phase 2 · NCT07616128 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 17, 2024First study: phase 2 study in Chronic Inducible UrticariaFirst studyNCT06603220 · 30 enrolled · United States
- Mar 7, 2025Phase 2 study in Chronic UrticariaNCT06873516 · 182 enrolled · United States, Canada, Japan
- Aug 28, 2025Phase 2 study in Dermatitis, AtopicNCT07150845 · 121 enrolled · United States, New Zealand
- May 19, 2026Phase 2 study in Migraine DisordersNCT07616128 · 330 planned · United States, Australia, Canada and more
Ahead
- Oct 2027Primary completion: phase 2 study in Migraine DisordersNCT07616128
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07616128Migraine Disorders · United States, Australia, Canada and more | 2 | Recruiting | Oct 2027 | 330 |
| NCT07150845Dermatitis, Atopic · United States, New Zealand | 2 | Completed | Jul 23, 2026 | 121 |
| NCT06873516Chronic Urticaria · United States, Canada, Japan | 2 | Completed | May 29, 2026 | 182 |
| NCT06603220Chronic Inducible Urticaria · United States | 2 | Completed | May 8, 2025 | 30 |
How it is read
Names in the registry
- “EVO756”, 6 entries
- “EVO756, Dose 1”, 1 entry
- “EVO756, Dose 2”, 1 entry
- “Oral EVO756 300 mg QD”, 1 entry
- “Oral EVO756 50 mg BID”, 1 entry
Codes read as this program: EVO756.
Conditions, from the studies’ own filings
- Migraine Disorders, 1 study
- Dermatitis, Atopic, 1 study
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.